⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RGNX News
REGENXBIO Inc.
REGENXBIO Announces Proposed Public Offering of Common Stock
prnewswire.com
RGNX
Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm
globenewswire.com
RGNX
Lifshitz Law PLLC Announces Investigations of Corcept Therapeutics, Inc. (NASDAQ: CORT), Gartner, Inc. (NYSE: IT), REGENXBIO Inc. (NASDAQ: RGNX), and Graphic Packaging Holding Company (NYSE: GPK)
accessnewswire.com
CORT
IT
RGNX
GPK
Form 8-K
sec.gov
RGNX
REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone
prnewswire.com
RGNX
REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026
prnewswire.com
RGNX
REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II
prnewswire.com
RGNX
Lifshitz Law PLLC Announces Investigations of BlackRock, TCP Capital Corp. (NASDAQ: TCPC), Oracle Corporation (NYSE: ORCL), REGENXBIO Inc. (NASDAQ: RGNX), and Inovio Pharmaceuticals, Inc. (NASDAQ: INO)
accessnewswire.com
TCPC
ORCL
RGNX
INO
Form 8-K
sec.gov
RGNX
REGENXBIO to Participate in Upcoming Investor Conferences
prnewswire.com
RGNX